IP Library Granted Patent US 7,879,983
Granted Patent B2
US 7,879,983 · App. 12/505,313 · Granted Feb 1, 2011

Binding member which binds to both Lewis-

Assignee: Cephalon Australia Pty Ltd
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,983
App. No.
12/505,313
Granted
Feb 1, 2011
Kind
B2
Abstract

The invention relates to the use of a binding member which binds to Lewis y and Lewis b haptens in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to Lewis y and Lewis b haptens and cancer cells and induces cells death.

Claims (5)

1. An isolated antibody or fragment thereof comprising all the complementarity determining regions (CDRs) of the antibody produced by the cell line deposited as ECACC Accession No. 01050118, which antibody or fragment thereof specifically binds to both Lewis y and Lewis b haptens and does not bind to H blood group hapten.

2. The isolated antibody as claimed in claim 1 , which is produced by the cell line deposited as ECACC Accession No. 01050118.

3. An isolated antibody fragment comprising all the complementarity determining regions (CDRs) produced by a cell line deposited as ECACC Accession No. 01050118, characterized by specifically binding to Lewis y and Lewis b and not binding to Lewis x .

4. The isolated antibody fragment of claim 3 , further characterized by not binding to H blood group antigen by thin layer chromatography.

5. An isolated antibody fragment comprising all the complementarity determining regions (CDRs) produced by a cell line deposited as ECACC Accession No. 01050118, characterized by specifically binding to Lewis y and Lewis b and not binding to H blood group antigen by thin layer chromatography.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECTION OF THE ASSIGNEE ADDRESS TO REMOVE "RON KAL" FROM THE ADDRESS PREVIOUSLY RECORDED ON REEL 031485 FRAME 0800. ASSIGNOR(S) HEREBY CONFIRMS THE NAME CHANGE FROM CEPHALON AUSTRALIA PTYLTD TO TEVA PHARMACEUTICALS AUSTRALIA PTY. Recorded Dec 9, 2013
From: CEPHALON AUSTRALIA PTY LTD
To: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Reel/Frame 032269/0198 →
CHANGE OF NAME Recorded Oct 24, 2013
From: CEPHALON AUSTRALIA PTY LTD
To: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Reel/Frame 031485/0800 →
CHANGE OF NAME Recorded Sep 2, 2010
From: ARANA THERAPEUTICS PTY LTD
To: CEPHALON AUSTRALIA PTY LTD
Reel/Frame 024929/0966 →
CHANGE OF NAME Recorded Sep 1, 2010
From: ARANA THERAPEUTICS LIMITED
To: ARANA THERAPEUTICS PTY LTD
Reel/Frame 024922/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2009
From: DURRANT, LINDA G.; PARSONS, TINA
To: SCANCELL LIMITED
Reel/Frame 022988/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2009
From: SCANCELL LIMITED
To: ARANA THERAPEUTICS LIMITED
Reel/Frame 022988/0786 →
Priority Claims (1)
GB 0111628.4 · May 11, 2001 · national
Continuity (3)
Continuation 11831125 · Jul 31, 2007
Continuation 10476233
Related Publication 20090281285A1 · Nov 12, 2009